Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07287137
PHASE4

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

View on ClinicalTrials.gov

Summary

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Official title: IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Key Details

Gender

All

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

54

Start Date

2025-11-12

Completion Date

2027-09

Last Updated

2025-12-17

Healthy Volunteers

Yes

Interventions

DRUG

Pfizer-BioNTech mRNA COVID-19 vaccine

COVID-19 Vaccine, mRNA

DRUG

Novavax recombinant protein vaccine

Recombinant protein vaccine

Locations (1)

Walter Reed National Military Medical Center

Bethesda, Maryland, United States